|
AU2003276858A8
|
|
Method of treating a systemic disease
|
|
US7056494B2
|
|
Method of treating a systemic disease
|
|
AU4751702A
|
|
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
|
US2003157153A1
|
|
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
|
|
WO02067905A1
|
|
A sustained release pharmaceutical formulation
|
|
AU5323301A
|
|
Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
|
|
EP1972635A1
|
|
Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
|
|
US6524615B2
|
|
Controlled release pharmaceutical composition
|
|
US6491950B1
|
|
Controlled release pharmaceutical composition
|
|
US6155251A
|
|
Breath coordinated inhaler
|
|
EP0999844A1
|
|
Pretreating hyperlipidemic individuals with a flush inhibiting agent prior to nicotinic acid therapy
|
|
AU6882698A
|
|
Breath coordinated inhaler
|
|
CA2283322A1
|
|
Starter kit containing nicotinic acid compositions
|
|
US6676967B1
|
|
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
|
US6746691B2
|
|
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
|
|
US6406715B1
|
|
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
|
|
US6818229B1
|
|
Intermediate release nicotinic acid compositions for treating hyperlipidemia
|
|
EP0866799A1
|
|
Apolipoprotein e2 and treatment of alzheimer's disease
|
|
US6020305A
|
|
Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors
|
|
US5855884A
|
|
Treatment of stress-induced migraine headache with a corticotropin releasing hormone blocker
|
